An internationally recognized pioneer in the field of cancer immunobiology, Greenberg has made groundbreaking contributions examining host T-cell responses to pathogenic viral infections. His work has led to crucial insights into the understanding of the mechanisms by which T cells distinguish tumor cells from normal cells and has fueled the advancement of adoptive T-cell therapy approaches in various cancers, including leukemia. His research also showed that CD4-positive helper T cells work both collaboratively and independently of CD8-positive cytotoxic T cells to eradicate tumor cells. This work has since been applied to the development of treatments for late-stage melanoma and leukemia.
Dr. Greenberg received his medical degree from the State University of New York, Downstate Medical Center, New York, in 1971; a Bachelor of Arts degree in biology from the Washington University, St. Louis, Missouri in 1967. He was a postdoctoral research fellow (1974-1976) in immunology, and intern and resident in medicine (1971-1974) at the University of California at San Diego, California.
Dr. Greenberg has been director of the Immunology Program, University of Washington Center for AIDS Research (1988-2003); associate professor (1982-1988) and assistant professor (1978-1982), Medicine, Division of Oncology, University of Washington School of Medicine; associate member (1982-1988) and assistant member (1978-1982), Fred Hutchinson Cancer Research Center; and senior fellow, Division of Oncology, University of Washington and the Fred Hutchinson Cancer Research Center (1976-1978), Seattle, Washington.
Elected fellow of AACR Academy in 2019, Dr. Greenberg has been a member of the Finance and Audit Committee (2019-2022); vice chair of the Annual Meeting Program Committee (2019-2020); member of the Board of Directors (2017-2020); member of the AACR Cancer Progress Report Steering Committee (2017-2018); member of the Annual Meeting Education Committee (2016-2017); cochair (2016) and member (2015) of the CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference Scientific Committee; editor-in-chief (2015-present) and senior editor (2012-2015) of Cancer Immunology Research; member of the Continuing Medical Education Committee (2014-present); member of the AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology Selection Committee (2012-2014); and member of the Editorial Board of Clinical Cancer Research (1994-1997).
Over the years, Dr. Greenberg has been elected fellow of the Society for Immunotherapy of Cancer Inaugural Class of Fellows of the Academy of Immuno-Oncology (2021); project leader of The Weill Neurohub Investigators Program (2021-present); recipient of the Precision Medicine World Conference Luminary Award (2020); elected distinguished fellow of the American Association of Immunologists (2019); recipient of the American Society of Hematology E. Donnall Thomas Prize for Pioneering Research Achievements in Hematology (2019); recipient of the Society for Immunotherapy of Cancer Richard Smalley Memorial Award (2018); investigator of the Parker Institute for Cancer Immunotherapy (2017-present); member of the Stand Up To Cancer Scientific Advisory Committee (2013-2019); recipient of the Cancer Research Institute’s William B. Coley Award for Distinguished Research in Tumor Immunology (2011); recipient of the International Society for Biologic Therapy Team Science Award for Career Achievements (2010); elected fellow of the American College of Physicians (ACP) (2008); elected fellow of the American Association for the Advancement of Science (AAAS) (2007); recipient of the National Institutes of Health MERIT Award (1999-2007); elected member of the Association of American Physicians (AAP) (1998); member of the NIH Office of AIDS Research Advisory Council (1998-2002); member of the Board of Scientific Counselors, NCI (1992-1996); and elected member of the American Society for Clinical Investigation (ASCI) (1987).